Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Wagner

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Clinical Immunology (Orlando, Fla.)|September 23, 2006
Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for badDavid H Wagner
Frontiers in Endocrinology|September 8, 2017
Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to DiabetogenesisDavid H Wagner
The Journal of Clinical Endocrinology and Metabolism|June 19, 2018
Challenges to Reshape the Future of Type 1 Diabetes ResearchDavid Bleich, David H Wagner
Plos One|May 1, 2008
High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunityGisela M Vaitaitis, David H Wagner
Cellular & Molecular Immunology|September 17, 2013
CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expressionGisela M Vaitaitis, David H Wagner
F1000Research|January 16, 2019
Are we aiming to miss in translational autoimmunity treatments?Gisela M Vaitaitis, David H Wagner
Plos One|June 12, 2012
Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunityGisela M Vaitaitis, David H Wagner
Molecular Immunology|July 22, 2010
CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunityGisela M Vaitaitis, David H Wagner
The Journal of Biological Chemistry|March 21, 2023
Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY<sub>15</sub>Gisela M Vaitaitis, David H Wagner
Neurology International|November 25, 2024
Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY<sub>6</sub> Is More Advantageous in Treating Ongoing Experimental Autoimmune EncephalomyelitisGisela M Vaitaitis, David H Wagner
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Clinical Immunology (Orlando, Fla.)|September 23, 2006
Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for badDavid H Wagner
Frontiers in Endocrinology|September 8, 2017
Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to DiabetogenesisDavid H Wagner
The Journal of Clinical Endocrinology and Metabolism|June 19, 2018
Challenges to Reshape the Future of Type 1 Diabetes ResearchDavid Bleich, David H Wagner
Plos One|May 1, 2008
High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunityGisela M Vaitaitis, David H Wagner
Cellular & Molecular Immunology|September 17, 2013
CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expressionGisela M Vaitaitis, David H Wagner
F1000Research|January 16, 2019
Are we aiming to miss in translational autoimmunity treatments?Gisela M Vaitaitis, David H Wagner
Plos One|June 12, 2012
Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunityGisela M Vaitaitis, David H Wagner
Molecular Immunology|July 22, 2010
CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunityGisela M Vaitaitis, David H Wagner
The Journal of Biological Chemistry|March 21, 2023
Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY<sub>15</sub>Gisela M Vaitaitis, David H Wagner
Neurology International|November 25, 2024
Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY<sub>6</sub> Is More Advantageous in Treating Ongoing Experimental Autoimmune EncephalomyelitisGisela M Vaitaitis, David H Wagner
Pageof 4